Calidi Biotherapeutics (CLDI) Accounts Payables (2021 - 2026)

Calidi Biotherapeutics has reported Accounts Payables for 6 years, with the latest figure at $930000.0 in Q2 2026.

• On a quarterly basis, Accounts Payables fell 23.46% year-over-year to $930000.0 in Q2 2026; TTM through Jun 2026 was $930000.0, a 23.46% decrease from a year earlier, with the FY2025 full-year figure at $595000.0, down 71.28% from the prior year.
• Accounts Payables was $930000.0 for Q2 2026 at Calidi Biotherapeutics, up from $595000.0 in the prior quarter.
• The five-year high for Accounts Payables was $6.8 million in Q3 2024, with the low at $27810.0 in Q2 2022.
• Average Accounts Payables over 5 years is $2.3 million, with a median of $1.1 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2025: Accounts Payables jumped 11843.45% in 2023, then slumped 83.19% in 2025.
• Over 5 years, Accounts Payables stood at $51074.0 in 2022, then surged by 11843.45% to $6.1 million in 2023, then tumbled by 66.03% to $2.1 million in 2024, then tumbled by 71.28% to $595000.0 in 2025, then jumped by 56.3% to $930000.0 in 2026.
• The last three Accounts Payables figures came in at $930000.0 (Q2 2026), $595000.0 (Q4 2025), and $1.1 million (Q3 2025), per Business Quant data.